A leading solution in target deconvolution and receptor identification
Retrogenix provides the leading solution for receptor and membrane target deconvolution. We specialise in discovering which human plasma membrane proteins are targeted by antibodies, proteins, small molecules and viruses.
Retrogenix identifies on behalf of its clients:
Target deconvolution is achieved by screening our clients’ molecules for interactions against the most comprehensive set of human plasma membrane proteins available in the context of the human cell. Now covering more than 3500 proteins, this represents the majority of known plasma membrane proteins.
Retrogenix has a rich client portfolio, including many global pharmaceutical / drug discovery companies and several notable academic institutions. We give our commercial clients a competitive advantage by identifying high quality, unexploited drug targets, and helping them to improve success rates at all stages of the drug research and development process.
19/08/2016 | Dr Freeth invited to speak at SLAS Europe conference. Retrogenix co-founder, Jim Freeth, has been invited to speak at the joint meeting of the Society for Laboratory Automation and Screening (SLAS) and the Spanish Drug Discovery Network. The meeting will run from 3rd – 4th November... | Read More
Retrogenix will be attending the European Antibody Congress / World Immunotherapy Congress from the 14th to the 16th of November in Basel, Switzerland | Find out more
"We are very pleased with the service Retrogenix provided to us. In less than two months they were able to identify and confirm the target specificity of multiple antibodies we provided to Retrogenix (over 70% of antibodies provided).This helped us to validate our internal technology development." | Read more
Professor Thomas Lavstsen, University of Copenhagen